FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3171568051> ?p ?o ?g. }

• W3171568051 endingPage "9532" @default.
• W3171568051 startingPage "9532" @default.
• W3171568051 abstract "9532 Background: Survival of BRAF-mutated melanoma profoundly improved since the introduction of immune checkpoint inhibitors (ICI) and MAPK pathway inhibitors (MAPKi). Response kinetics of ICI and MAPKi are complementary, mechanistic evidence indicates that MAPKi may affect the tumor immune microenvironment. Combined use of both drug classes may further enhance clinical benefit. IMMU-Target was set-up as a prospective, open-label, phase I/II trial, with a safety phase I part followed by a randomized phase II part, to study the tolerability and clinical activity of PEM, ENC and BIN triplet therapy. Methods: Treatment naïve adult patients (pts) with stage IIIB-IV (AJCC 2017), BRAF V600 mutant melanoma with measurable disease but no active brain metastasis were eligible. The dose finding part used a 3+3 design, starting with a dose level (DL) 0 applying the clinically recommended doses of PEM (200 mg Q3W), ENC (450 mg QD) and BIN (45 mg BID). In case of ≥2 dose-limiting toxicities (DLT), a reduction of the ENC and BIN doses (300 mg QD and 30 mg BID at DL-1, 200 mg QD and 30 mg BID at DL -2) was foreseen. Primary endpoints of the phase I part were safety and tolerability. Results: From April 2018 until May 2020, 14 pts with BRAF V600 mutations were enrolled. 2 of 3 pts at DL 0 developed DLT (creatine phosphokinase (CPK) elevations grade 3 plus cytokine release syndrome grade 4; gamma glutamyl transferase (GGT) elevations grade 3), and had to stop therapy early. Therefore, 3+3 further pts at DL -1 were included with no DLT observed in these 6 pts. One (isolated GGT elevations grade 3) of the 2 DLT observed in the 3 pts of DL 0 enrolled initially was questionable as DLT, as the patient had further episodes of isolated GGT elevations without therapy. As a result, further 5 pts were enrolled at DL 0: here no DLT-matching treatment-related adverse event (TRAE) occurred. In total, 12 out of 14 pts (86%) experienced a TRAE and 7 (50%) experienced a grade ≥3 TRAE; there were no fatal AE or TRAE-related deaths. Increases in alanine and in aspartate aminotransferases, GGT and CPK elevations (6 of 14 pts) were the most common grade 3-4 TRAE. In median, pts at DL 0 (n=8) received triplet therapy for 18 weeks (IQR 7.5-29), at DL-1 (n=6) for 46 weeks (IQR 27-102). The overall response rate was 64% (95% CI=35-87). At a median follow-up of 10.0 months at DL 0 and 27.0 months at DL-1, progression-free survival at 12 months was 37.5% (95% CI 9- 67) and 60% (95% CI 13-88), respectively. Conclusions: Triplet therapy was feasible and safe at both dose levels leading to clinically meaningful disease control. The phase II part was not initiated, since the clinical efficacy of PEM plus ENC and BIN is currently investigated in STARBOARD ( NCT04657991 ), a prospective, randomized, placebo-controlled (PEM mono), double-blinded phase III trial. Clinical trial information: NCT02902042." @default.
• W3171568051 created "2021-06-22" @default.
• W3171568051 creator A5014442576 @default.
• W3171568051 creator A5018314489 @default.
• W3171568051 creator A5019738186 @default.
• W3171568051 creator A5034365278 @default.
• W3171568051 creator A5047444289 @default.
• W3171568051 creator A5049229784 @default.
• W3171568051 creator A5064923908 @default.
• W3171568051 creator A5075123441 @default.
• W3171568051 date "2021-05-20" @default.
• W3171568051 modified "2023-09-26" @default.
• W3171568051 title "Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma: Final results from the dose-finding phase I part of the IMMU-Target trial." @default.
• W3171568051 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.9532" @default.
• W3171568051 hasPublicationYear "2021" @default.
• W3171568051 type Work @default.
• W3171568051 sameAs 3171568051 @default.
• W3171568051 citedByCount "4" @default.
• W3171568051 countsByYear W31715680512021 @default.
• W3171568051 countsByYear W31715680512022 @default.
• W3171568051 countsByYear W31715680512023 @default.
• W3171568051 crossrefType "journal-article" @default.
• W3171568051 hasAuthorship W3171568051A5014442576 @default.
• W3171568051 hasAuthorship W3171568051A5018314489 @default.
• W3171568051 hasAuthorship W3171568051A5019738186 @default.
• W3171568051 hasAuthorship W3171568051A5034365278 @default.
• W3171568051 hasAuthorship W3171568051A5047444289 @default.
• W3171568051 hasAuthorship W3171568051A5049229784 @default.
• W3171568051 hasAuthorship W3171568051A5064923908 @default.
• W3171568051 hasAuthorship W3171568051A5075123441 @default.
• W3171568051 hasConcept C121608353 @default.
• W3171568051 hasConcept C126322002 @default.
• W3171568051 hasConcept C143998085 @default.
• W3171568051 hasConcept C197934379 @default.
• W3171568051 hasConcept C2777658100 @default.
• W3171568051 hasConcept C2777701055 @default.
• W3171568051 hasConcept C2778375690 @default.
• W3171568051 hasConcept C2778715236 @default.
• W3171568051 hasConcept C2780057760 @default.
• W3171568051 hasConcept C31760486 @default.
• W3171568051 hasConcept C502942594 @default.
• W3171568051 hasConcept C535046627 @default.
• W3171568051 hasConcept C71924100 @default.
• W3171568051 hasConcept C90924648 @default.
• W3171568051 hasConcept C98274493 @default.
• W3171568051 hasConceptScore W3171568051C121608353 @default.
• W3171568051 hasConceptScore W3171568051C126322002 @default.
• W3171568051 hasConceptScore W3171568051C143998085 @default.
• W3171568051 hasConceptScore W3171568051C197934379 @default.
• W3171568051 hasConceptScore W3171568051C2777658100 @default.
• W3171568051 hasConceptScore W3171568051C2777701055 @default.
• W3171568051 hasConceptScore W3171568051C2778375690 @default.
• W3171568051 hasConceptScore W3171568051C2778715236 @default.
• W3171568051 hasConceptScore W3171568051C2780057760 @default.
• W3171568051 hasConceptScore W3171568051C31760486 @default.
• W3171568051 hasConceptScore W3171568051C502942594 @default.
• W3171568051 hasConceptScore W3171568051C535046627 @default.
• W3171568051 hasConceptScore W3171568051C71924100 @default.
• W3171568051 hasConceptScore W3171568051C90924648 @default.
• W3171568051 hasConceptScore W3171568051C98274493 @default.
• W3171568051 hasIssue "15_suppl" @default.
• W3171568051 hasLocation W31715680511 @default.
• W3171568051 hasOpenAccess W3171568051 @default.
• W3171568051 hasPrimaryLocation W31715680511 @default.
• W3171568051 hasRelatedWork W2054186137 @default.
• W3171568051 hasRelatedWork W2089245388 @default.
• W3171568051 hasRelatedWork W2518309888 @default.
• W3171568051 hasRelatedWork W2792428998 @default.
• W3171568051 hasRelatedWork W2896659597 @default.
• W3171568051 hasRelatedWork W2996750011 @default.
• W3171568051 hasRelatedWork W3115293888 @default.
• W3171568051 hasRelatedWork W3172600265 @default.
• W3171568051 hasRelatedWork W4225695268 @default.
• W3171568051 hasRelatedWork W4320710015 @default.
• W3171568051 hasVolume "39" @default.
• W3171568051 isParatext "false" @default.
• W3171568051 isRetracted "false" @default.
• W3171568051 magId "3171568051" @default.
• W3171568051 workType "article" @default.